Orexo AB (ORX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Orexo AB (ORX) has a cash flow conversion efficiency ratio of -0.344x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-93.30 Million ≈ $-10.04 Million USD) by net assets (Skr271.30 Million ≈ $29.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ORX stock market capitalisation for the company's overall valuation and market capitalisation.
Orexo AB - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Orexo AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Orexo AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orexo AB ranked by their cash flow conversion efficiency. Explore Orexo AB (ORX) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TagMaster AB Series B
ST:TAGM-B
|
0.129x |
|
British Land Company PLC
LSE:BLND
|
0.025x |
|
Anson Resources Limited
F:9MY
|
-0.046x |
|
Full Wang International Development Co Ltd
TWO:6219
|
-0.136x |
|
Hardwyn India Limited
NSE:HARDWYN
|
0.012x |
|
OFS Capital Corp
NASDAQ:OFS
|
0.154x |
|
EQ Inc.
V:EQ
|
-0.293x |
|
PJ Metal Co. Ltd
KQ:128660
|
-0.274x |
Annual Cash Flow Conversion Efficiency for Orexo AB (2002–2025)
The table below shows the annual cash flow conversion efficiency of Orexo AB from 2002 to 2025. View ORX stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr490.60 Million ≈ $52.80 Million |
Skr173.00 Million ≈ $18.62 Million |
0.353x | +36.20% |
| 2024-12-31 | Skr-126.30 Million ≈ $-13.59 Million |
Skr-32.70 Million ≈ $-3.52 Million |
0.259x | +116.05% |
| 2023-12-31 | Skr58.90 Million ≈ $6.34 Million |
Skr-95.00 Million ≈ $-10.22 Million |
-1.613x | -99.71% |
| 2022-12-31 | Skr193.90 Million ≈ $20.87 Million |
Skr-156.60 Million ≈ $-16.85 Million |
-0.808x | -23.30% |
| 2021-12-31 | Skr349.60 Million ≈ $37.62 Million |
Skr-229.00 Million ≈ $-24.64 Million |
-0.655x | -2277.60% |
| 2020-12-31 | Skr558.50 Million ≈ $60.10 Million |
Skr16.80 Million ≈ $1.81 Million |
0.030x | -92.60% |
| 2019-12-31 | Skr706.40 Million ≈ $76.02 Million |
Skr287.00 Million ≈ $30.89 Million |
0.406x | -20.07% |
| 2018-12-31 | Skr476.10 Million ≈ $51.24 Million |
Skr242.00 Million ≈ $26.04 Million |
0.508x | +14.11% |
| 2017-12-31 | Skr329.10 Million ≈ $35.42 Million |
Skr146.60 Million ≈ $15.78 Million |
0.445x | -11.51% |
| 2016-12-31 | Skr310.30 Million ≈ $33.39 Million |
Skr156.20 Million ≈ $16.81 Million |
0.503x | +231.25% |
| 2015-12-31 | Skr266.46 Million ≈ $28.68 Million |
Skr-102.19 Million ≈ $-11.00 Million |
-0.384x | +64.19% |
| 2014-12-31 | Skr455.02 Million ≈ $48.97 Million |
Skr-487.30 Million ≈ $-52.44 Million |
-1.071x | +34.30% |
| 2013-12-31 | Skr161.46 Million ≈ $17.38 Million |
Skr-263.20 Million ≈ $-28.32 Million |
-1.630x | -1187.18% |
| 2012-12-31 | Skr191.19 Million ≈ $20.58 Million |
Skr28.67 Million ≈ $3.09 Million |
0.150x | +139.79% |
| 2011-12-31 | Skr311.10 Million ≈ $33.48 Million |
Skr-117.23 Million ≈ $-12.62 Million |
-0.377x | -310.64% |
| 2010-12-31 | Skr468.24 Million ≈ $50.39 Million |
Skr-42.97 Million ≈ $-4.62 Million |
-0.092x | +62.41% |
| 2009-12-31 | Skr548.66 Million ≈ $59.04 Million |
Skr-133.93 Million ≈ $-14.41 Million |
-0.244x | -37.04% |
| 2008-12-31 | Skr569.78 Million ≈ $61.32 Million |
Skr-101.49 Million ≈ $-10.92 Million |
-0.178x | +25.50% |
| 2007-12-31 | Skr671.25 Million ≈ $72.24 Million |
Skr-160.49 Million ≈ $-17.27 Million |
-0.239x | -206.76% |
| 2006-12-31 | Skr324.35 Million ≈ $34.91 Million |
Skr-25.28 Million ≈ $-2.72 Million |
-0.078x | +41.80% |
| 2005-12-31 | Skr338.91 Million ≈ $36.47 Million |
Skr-45.38 Million ≈ $-4.88 Million |
-0.134x | +33.29% |
| 2004-12-31 | Skr79.44 Million ≈ $8.55 Million |
Skr-15.94 Million ≈ $-1.72 Million |
-0.201x | +73.90% |
| 2003-12-31 | Skr35.88 Million ≈ $3.86 Million |
Skr-27.59 Million ≈ $-2.97 Million |
-0.769x | +5.68% |
| 2002-12-31 | Skr25.52 Million ≈ $2.75 Million |
Skr-20.80 Million ≈ $-2.24 Million |
-0.815x | -- |
About Orexo AB
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabac… Read more